Yuan T, Bi F, Hu K, Zhu Y, Lin Y, Yang J
Clin Pharmacokinet. 2024; 63(8):1147-1165.
PMID: 39102093
DOI: 10.1007/s40262-024-01404-0.
Klyushova L, Perepechaeva M, Grishanova A
Biomedicines. 2022; 10(11).
PMID: 36359206
PMC: 9687714.
DOI: 10.3390/biomedicines10112686.
Lee M, Jeong Y, Kim M, An K, Chung S
Pharmaceutics. 2022; 14(6).
PMID: 35745730
PMC: 9227536.
DOI: 10.3390/pharmaceutics14061157.
Wang Z, Paragas E, Nagar S, Korzekwa K
Drug Metab Dispos. 2021; 49(12):1090-1099.
PMID: 34503952
PMC: 11022900.
DOI: 10.1124/dmd.121.000553.
Burt T, Young G, Lee W, Kusuhara H, Langer O, Rowland M
Nat Rev Drug Discov. 2020; 19(11):801-818.
PMID: 32901140
DOI: 10.1038/s41573-020-0080-x.
inhibitory effects of ganoderic acid A on human liver cytochrome P450 enzymes.
Xu S, Zhang F, Chen D, Su K, Zhang L, Jiang R
Pharm Biol. 2020; 58(1):308-313.
PMID: 32285742
PMC: 7178866.
DOI: 10.1080/13880209.2020.1747500.
inhibitory effects of cepharanthine on human liver cytochrome P450 enzymes.
Zhang X, Feng P, Gao X, Wang B, Gou C, Bian R
Pharm Biol. 2020; 58(1):247-252.
PMID: 32223485
PMC: 7170383.
DOI: 10.1080/13880209.2020.1741650.
inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes.
Zhang N, Liu J, Chen Z, Dou W
Pharm Biol. 2019; 57(1):571-576.
PMID: 31456483
PMC: 6720019.
DOI: 10.1080/13880209.2019.1656257.
In vitro inhibitory effects of bergenin on human liver cytochrome P450 enzymes.
Dong G, Zhou Y, Song X
Pharm Biol. 2019; 56(1):620-625.
PMID: 31070542
PMC: 6282425.
DOI: 10.1080/13880209.2018.1525413.
MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.
Lavezzi S, Mezzalana E, Zamuner S, De Nicolao G, Ma P, Simeoni M
J Pharmacokinet Pharmacodyn. 2018; 45(6):787-802.
PMID: 30415351
DOI: 10.1007/s10928-018-9608-7.
In vitro inhibitory effects of Friedelin on human liver cytochrome P450 enzymes.
Wei J, Zhang H, Zhao Q
Pharm Biol. 2018; 56(1):363-367.
PMID: 30122094
PMC: 6130513.
DOI: 10.1080/13880209.2018.1491999.
In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes.
Liu L, Sun S, Rui H, Li X
Pharm Biol. 2017; 55(1):1868-1874.
PMID: 28614988
PMC: 7012011.
DOI: 10.1080/13880209.2017.1339284.
A Cytochrome P450 3A4 Biosensor Based on Generation 4.0 PAMAM Dendrimers for the Detection of Caffeine.
Muller M, Agarwal N, Kim J
Biosensors (Basel). 2016; 6(3).
PMID: 27548239
PMC: 5039663.
DOI: 10.3390/bios6030044.
Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS.
Fallon J, Smith P, Xia C, Kim M
Pharm Res. 2016; 33(9):2280-8.
PMID: 27356525
DOI: 10.1007/s11095-016-1966-5.
Inhibitory Effects of Triptolide on Human Liver Cytochrome P450 Enzymes and P-Glycoprotein.
Zhang H, Ya G, Rui H
Eur J Drug Metab Pharmacokinet. 2016; 42(1):89-98.
PMID: 26874845
DOI: 10.1007/s13318-016-0323-8.
Improved proteostasis in the secretory pathway rescues Alzheimer's disease in the mouse.
Peng Y, Kim M, Hullinger R, ORiordan K, Burger C, Pehar M
Brain. 2016; 139(Pt 3):937-52.
PMID: 26787453
PMC: 4805081.
DOI: 10.1093/brain/awv385.
Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.
Filppula A, Laitila J, Neuvonen P, Backman J
Br J Pharmacol. 2011; 165(8):2787-98.
PMID: 22014153
PMC: 3423228.
DOI: 10.1111/j.1476-5381.2011.01732.x.
NMR-derived models of amidopyrine and its metabolites in complexes with rabbit cytochrome P450 2B4 reveal a structural mechanism of sequential N-dealkylation.
Roberts A, Sjogren S, Fomina N, Vu K, Almutairi A, Halpert J
Biochemistry. 2011; 50(12):2123-34.
PMID: 21375273
PMC: 3163098.
DOI: 10.1021/bi101797v.
Predicting drug-drug interactions: an FDA perspective.
Zhang L, Zhang Y, Zhao P, Huang S
AAPS J. 2009; 11(2):300-6.
PMID: 19418230
PMC: 2691466.
DOI: 10.1208/s12248-009-9106-3.
Prediction of hepatic clearance in human from in vitro data for successful drug development.
Chiba M, Ishii Y, Sugiyama Y
AAPS J. 2009; 11(2):262-76.
PMID: 19408130
PMC: 2691463.
DOI: 10.1208/s12248-009-9103-6.